{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:46Z","timestamp":1792460146617,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-024-04837-0","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:01:31Z","timestamp":1728345691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Significance of early diagnosis and treatment of adult late-onset Pompe disease on the effectiveness of enzyme replacement therapy in improving muscle strength and respiratory function: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-4905","authenticated-orcid":false,"given":"Moein","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-7828","authenticated-orcid":false,"given":"Kianmehr","family":"Rouhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-0959","authenticated-orcid":false,"given":"Kiana","family":"Rouhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-4850","authenticated-orcid":false,"given":"Mohammadjavad","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-5109","authenticated-orcid":false,"given":"Mohammadrafi","family":"Damirchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-3054","authenticated-orcid":false,"given":"Sajjad","family":"Yazdansetad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0143-7306","authenticated-orcid":false,"given":"Mehrdad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"4837_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.nmd.2018.03.011","volume":"28","author":"M Savarese","year":"2018","unstructured":"Savarese M, Torella A, Musumeci O, Angelini C, Astrea G, Bello L, et\u00a0al. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. Neuromuscul Disord. 2018;28:586\u201391.","journal-title":"Neuromuscul Disord"},{"key":"4837_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/biom13091279","volume":"13","author":"B Labella","year":"2023","unstructured":"Labella B, Cotti Piccinelli S, Risi B, Caria F, Damioli S, Bertella E, et\u00a0al. A Comprehensive update on late-onset pompe disease. Biomolecules. 2023;13:1279.","journal-title":"Biomolecules"},{"key":"4837_CR3","doi-asserted-by":"publisher","first-page":"1310317","DOI":"10.3389\/fped.2024.1310317","volume":"12","author":"AD Dornelles","year":"2024","unstructured":"Dornelles AD, Junges APP, Krug B, Gon\u00e7alves C, de Oliveira Junior HA, Schwartz IVD. Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis. Front Pediatr. 2024;12:1310317.","journal-title":"Front Pediatr"},{"key":"4837_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14737175.2024.2306855","volume":"24","author":"C Angelini","year":"2024","unstructured":"Angelini C. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease. Expert Rev Neurother. 2024;24:259\u201366.","journal-title":"Expert Rev Neurother"},{"key":"4837_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et\u00a0al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120:163\u201372.","journal-title":"Mol Genet Metab"},{"key":"4837_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/biom10091339","volume":"10","author":"NK Meena","year":"2020","unstructured":"Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10:1339.","journal-title":"Biomolecules"},{"key":"4837_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg A, Carlier PG, Carlier R-Y, Kissel JT, Schoser B, Wenninger S, et\u00a0al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study. Mol Genet Metab. 2016;119:115\u201323.","journal-title":"Mol Genet Metab"},{"key":"4837_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.molmed.2019.08.005","volume":"25","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Austin GL, Shaffer R, Armstrong DD, Gentry MS. Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases. Trends Mol Med. 2019;25:1094\u2013109.","journal-title":"Trends Mol Med"},{"key":"4837_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pediatrneurol.2011.12.010","volume":"46","author":"Y-H Chien","year":"2012","unstructured":"Chien Y-H, Lee N-C, Huang P-H, Lee W-T, Thurberg BL, Hwu W-L. Early pathologic changes and responses to treatment in patients with later-onset pompe disease. Pediatr Neurol. 2012;46:168\u201371.","journal-title":"Pediatr Neurol"},{"key":"4837_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/crj.13150","volume":"14","author":"A Jezela-Stanek","year":"2020","unstructured":"Jezela-Stanek A, Chorostowska-Wynimko J, Tylki-Szyma\u0144ska A. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: a state-of-the art review. Clin Respir J. 2020;14:422\u20139.","journal-title":"Clin Respir J"},{"key":"4837_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-018-0824-4","volume":"13","author":"JC van der Meijden","year":"2018","unstructured":"van der Meijden JC, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Beek NAME, van der Ploeg AT. Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients. Orphanet J Rare Dis. 2018;13:82.","journal-title":"Orphanet J Rare Dis"},{"key":"4837_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000521524","volume":"14","author":"J Al-Hashel","year":"2022","unstructured":"Al-Hashel J, Ismail I. Late-onset Pompe disease presenting with isolated tongue involvement. Case Rep Neurol. 2022;14:98\u2013103.","journal-title":"Case Rep Neurol"},{"key":"4837_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40248-018-0145-4","volume":"13","author":"F Menzella","year":"2018","unstructured":"Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N. Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. Multidiscip Respir Med. 2018;13:32.","journal-title":"Multidiscip Respir Med"},{"key":"4837_CR14","first-page":"45","volume-title":"Bioimpedance analysis as a method to evaluate the proportion of fatty and muscle tissues in progressive myopathy in Pompe disease","author":"A R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska","year":"2015","unstructured":"R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska A, Jurkiewicz E, Tylki-Szyma\u0144ska A. Bioimpedance analysis as a method to evaluate the proportion of fatty and muscle tissues in progressive myopathy in Pompe disease. Berlin Heidelberg: Springer, Berlin Heidelberg; 2015. p. 45\u201351."},{"key":"4837_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/ene.15222","volume":"29","author":"C Tard","year":"2022","unstructured":"Tard C, Salort-Campana E, Michaud M, Spinazzi M, Nadaj Pakleza A, Durr H, et\u00a0al. Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic. Eur J Neurol. 2022;29:1181\u20136.","journal-title":"Eur J Neurol"},{"key":"4837_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Lafor\u00eat P, Angelini C, Lachmann RH, et\u00a0al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24:768.","journal-title":"Eur J Neurol"},{"key":"4837_CR17","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","volume":"267","author":"DW Stockton","year":"2020","unstructured":"Stockton DW, Kishnani P, van der Ploeg A, Llerena J, Boentert M, Roberts M, et\u00a0al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267:3038\u201353.","journal-title":"J Neurol"},{"key":"4837_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini C, De Antonio M, Taouagh N, B\u00e9hin A, Bouhour F, Echaniz-Laguna A, et\u00a0al. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe registry. J Inherit Metab Dis. 2020;43:1219\u201331.","journal-title":"J Inherit Metab Dis"},{"key":"4837_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3390\/ijms17101735","volume":"17","author":"M Boentert","year":"2016","unstructured":"Boentert M, Prigent H, V\u00e1rdi K, Jones H, Mellies U, Simonds A, et\u00a0al. Practical Recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease. Int J Mol Sci. 2016;17:1735.","journal-title":"Int J Mol Sci"},{"key":"4837_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neurol.2022.12.004","volume":"179","author":"C Gu\u00e9my","year":"2023","unstructured":"Gu\u00e9my C, Lafor\u00eat P. The new horizons for treatment of late-onset Pompe disease (LOPD). Rev Neurol. 2023;179:81\u20139.","journal-title":"Rev Neurol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04837-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04837-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04837-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:08:57Z","timestamp":1728371337000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04837-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4837"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04837-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Golestan University of Medical Sciences with under the ethical code IR.GOUMS.REC.1401.387.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"486"}}